Standard BioTools Inc. Lessor, Operating Lease, Payment to be Received, Year Three
Standard BioTools Inc. (LAB) had Lessor, Operating Lease, Payment to be Received, Year Three of $1.48 million as of 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Leases › Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity
us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears · last filed 2026-03-16
- 2025-12-31: Lessor, Operating Lease, Payment to be Received, Year Three $1.48M.
- 2024-12-31: Lessor, Operating Lease, Payment to be Received, Year Three $1.43M.
- 2023-12-31: Lessor, Operating Lease, Payment to be Received, Year Three $1.38M.
- 2022-12-31: Lessor, Operating Lease, Payment to be Received, Year Three $1.64M.
| Period end | Lessor, Operating Lease, Payment to be Received, Year Three |
|---|---|
| 2025-12-31 | $1.48M 10-K · filed 2026-03-16 |
| 2024-12-31 | $1.43M 10-K · filed 2025-03-11 |
| 2023-12-31 | $1.38M 10-K · filed 2024-03-01 |
| 2022-12-31 | $1.64M 10-K · filed 2023-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |